A seasoned regulatory, quality and drug development executive, Dr. Mansell joins Spruce from AskBio, where she led regulatory affairs until the company’s acquisition by Bayer. She also built and led White Oak BioPharma Solutions, a global regulatory strategy and operations consulting firm where Dr. Mansell served on the executive teams for a full range of organizations, from startups to large, global companies. Prior to consulting, Dr. Mansell held positions of increasing responsibility in regulatory affairs, pharmacovigilance, quality affairs and CMC with several biotechnology and pharmaceutical companies, including Curis, Sigma-Tau Research, Genzyme, CombinatoRx, Millennium Pharmaceuticals and Boehringer Ingelheim Pharmaceuticals. Dr. Mansell earned a PhD in pharmacokinetics and biopharmaceutics with a graduate minor in applied statistics from Oregon State University and an MBA in finance and international business from New York University. With her orphan disease expertise and passion for rare endocrine disorders, Dr. Mansell is a strong addition to Spruce’s leadership team as the Company progresses tildacerfont through clinical development for adults and children with classic congenital adrenal hyperplasia and women with polycystic ovary syndrome, and advances its pipeline of additional novel rare endocrine therapeutics.